Google
Trusted Resources: Community Center
Online support, community stories, financial assistance
SOM Biotech – Linkedin
SOM Biotech is a clinical-stage drug discovery and development company based in Barcelona, Spain, with an office in the US, focused on repurposing drugs for CNS orphan indications. Its drug discovery is based on a proprietary artificial intelligence repurposing technology which has demonstrated success through the worldwide licensing of the company’s asset for TTR-Amyloidosis to a pharmaceutical company based in the US.
Currently, SOM Biotech has two clinical-stage assets for Huntington’s Disease (SOM3355) and Adrenoleukodystrophy (SOM1201), as well as a pool of preclinical-stage assets. SOM Biotech seeks strategic collaborations through licensing of its clinical-stage assets and co-development of new projects.
myBinderRelated Content
-
Clinical Trials: Benefits, Risks, and SafetyYou may ask yourself, "Why should I tr...
-
Doctors Making Progress in Treating AmyloidosisAmyloidosis is a rare condition that use...
-
Informed Consent for Clinical TrialsThe term informed consent is mistakenl...
-
Amyloid Center, Stanford Health CareThe Amyloidosis center at Stanford Healt...
-
Progress in Amyloidosis Research: Where Are We Now? – Webinarhttps://www.youtube.com/watch?v=8Yhv87Xo...
-
Stephen J. Kennel, PhDStephen J. Kennel is Professor at The Un...
-
University of Miami Health System, Sylvester Comprehensive Cancer CenterAmyloidosis is a rare protein depositi...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
